特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

腫瘍溶解性ウイルス免疫療法の世界市場

Global Market Study on Oncolytic Virus Immunotherapy: The Future Lies in Faster Approval for Multiple Adjuvant-line Therapies

発行 Persistence Market Research 商品コード 917599
出版日 ページ情報 英文 119 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=106.61円で換算しております。
腫瘍溶解性ウイルス免疫療法の世界市場 Global Market Study on Oncolytic Virus Immunotherapy: The Future Lies in Faster Approval for Multiple Adjuvant-line Therapies
出版日: 2019年10月16日 ページ情報: 英文 119 Pages
概要

当レポートは世界の腫瘍溶解性ウイルス免疫療法市場について調査しており、市場機会、成長および阻害要因、適応症・エンドユーザー・地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の概要

  • 市場調査範囲/分類
  • 市場の定義/範囲/制限

第3章 主な市場動向

  • 市場に影響を与える主な動向
  • 製品革新/開発動向

第4章 主な結論

  • 製品の採用/使用分析
  • 製品USP /機能
  • 産業の確立:制度的提携
  • 腫瘍溶解性ウイルス療法のユニークな送達方法の識別

第5章 市場需要(売上/規模)の分析および予測

  • 過去の市場分析
  • 現在・今後の市場予測
    • 前年比成長動向分析

第6章 市場の背景

  • マクロ経済要因
    • 世界のGDP成長見通し
    • 世界のヘルスケア産業の見通し
  • 予測要因:関連および影響
    • 腫瘍溶解性ウイルス免疫療法の採用
    • 進行中の臨床試験
    • 腫瘍溶解性ウイルス免疫療法への規制課題
    • 腫瘍溶解性ウイルス免疫療法の進歩
    • 増分R&D:製品ベースの企業別
  • GMPの規制シナリオ
  • バリューチェーン
  • 市場力学
    • 成長要因
    • 阻害要因
    • 市場機会分析

第7章 ベンチャーキャピタルファイナンス

第8章 パイプライン分析

第9章 市場分析:適応症別

  • イントロダクション/主な調査結果
  • 過去の市場分析
  • 現在・今後の市場分析および予測
    • 黒色腫
  • 市場の魅力分析

第10章 市場分析:エンドユーザー別

  • イントロダクション/主な調査結果
  • 過去の市場分析
  • 現在・今後の市場分析および予測
    • 病院
    • 専門クリニック
    • がん研究所
  • 市場の魅力分析

第11章 市場分析:地域別

  • イントロダクション
  • 過去の市場分析
  • 現在・今後の市場分析および予測
    • 北米
    • 欧州
  • 市場の魅力分析

第12章 競争分析

  • 競合ダッシュボード
  • 企業プロファイル
    • BioVex, Inc. (Amgen, Inc.)
    • Cold Genesys, Inc.
    • DNAtrix Therapeutics
    • Genelux Corporation
    • Lokon Pharma AB
    • Oncolytics Biotech, Inc.
    • ORYX GmbH & Co. KG
    • PsiOxus Therapeutics
    • SillaJen, Inc.
    • Sorrento Therapeutics, Inc.
    • Takara Bio
    • Targovax ASA
    • Transgene sa
    • Turnstone Biologics
    • VCN Biosciences
    • Viralytics Ltd. (Merck & Co., Inc.)
    • Vyriad
    • Shanghai Sunway Biotech

第13章 前提条件および略語の使用

第14章 調査方法

図表

List of Tables

  • Table 01: Prevalence of Cancer in North America, 2017
  • Table 02: Prevalence of Cancer in Latin America, 2017
  • Table 03: Prevalence of Cancer in Asia Pacific, 2017
  • Table 04: Prevalence of Cancer in Europe, 2017
  • Table 05: Number of FDA Approvals (2010-2017)
  • Table 06: Expenditure on Health, (% of GDP), by Country, 2016 - 2021
  • Table 07: Expenditure on Health, (% of GDP), by Country, 2016 - 2021
  • Table 08: Funding by Research Areas 2017 (US $Millions)
  • Table 09: Funding by Research Areas 2017 (US $Millions)
  • Table 10: Estimated Number of Deaths for the Four Major Cancers by Sex and Age Group, 2017
  • Table 11: Global Oncolytic Virus Immunotherapy Market Deals and Collaborations (1/2)
  • Table 12: Global Oncolytic Virus Immunotherapy Market Deals and Collaborations (2/2)
  • Table 13: Oncolytic Virus Immunotherapy Market Top Oncolytic Virus Projects (1/2)
  • Table 14: Oncolytic Virus Immunotherapy Market Top Oncolytic Virus Projects (2/2)
  • Table 15: Oncolytic Virus Immunotherapy Market Top Oncolytic Virus Projects (3/3)
  • Table 16: Oncolytic Virus Immunotherapy Pipeline Analysis By Virus Type (1/7)
  • Table 17: Oncolytic Virus Immunotherapy Pipeline Analysis By Virus Type (2/7)
  • Table 18: Oncolytic Virus Immunotherapy Pipeline Analysis By Virus Type (3/7)
  • Table 19: Oncolytic Virus Immunotherapy Pipeline Analysis By Virus Type (4/7)
  • Table 20: Oncolytic Virus Immunotherapy Pipeline Analysis By Virus Type (5/7)
  • Table 21: Oncolytic Virus Immunotherapy Pipeline Analysis By Virus Type (6/7)
  • Table 22: Oncolytic Virus Immunotherapy Pipeline Analysis By Virus Type (7/7)
  • Table 23: Global Oncolytic Virus Immunotherapy Market Size (US$ Mn) Analysis 2015-2018 and Forecast 2019-2029, By End User
  • Table 24: Global Oncolytic Virus Immunotherapy Market Size (US$ Mn) Analysis 2015-2018 and Forecast 2019-2029, By Region

List of Figures

  • Figure 01: Global Oncolytic Virus Immunotherapy Market Value Share By Indications (2019 E)
  • Figure 02: Global Oncolytic Virus Immunotherapy Market Value Share By End User (2019 E)
  • Figure 03: Global Oncolytic Virus Immunotherapy Market Value Share By Regions (2019 E)
  • Figure 04: Number of FDA approved pharmaceuticals (2010-2017)
  • Figure 05: Global Healthcare Expenditure in US$ Tn (2013-2020)
  • Figure 06: New Cancer Drugs Approved Each Year
  • Figure 07: Estimates of National Expenditures for Cancer Care (In Billions Of Dollars) by Cancer Site and Year
  • Figure 08: Distribution of Industry sponsored Pipeline Projects for Oncolytic Virus Immunotherapy, by Indication
  • Figure 09: Distribution of Industry sponsored Pipeline Projects for Oncolytic Virus Immunotherapy By Phase
  • Figure 10: Global Oncolytic Virus Immunotherapy Market Value (US$ Mn) Opportunity Assessment 2019-2029 (Optimistic Scenario)
  • Figure 11: Global Oncolytic Virus Immunotherapy Market Value (US$ Mn) Opportunity Assessment 2019-2029 (Conservative Scenario)
  • Figure 12: Global Oncolytic Virus Immunotherapy Market Value (US$ Mn) Opportunity Assessment 2019-2029 (Likely Scenario)
  • Figure 13: Global Oncolytic Virus Immunotherapy Market Value Analysis (US$ Mn), 2015-2018
  • Figure 14: Global Oncolytic Virus Immunotherapy Market Value Analysis (US$ Mn), 2019-2029
  • Figure 15: Global Oncolytic Virus Immunotherapy Market Absolute $ Opportunity, 2015-2018
  • Figure 16: Global Oncolytic Virus Immunotherapy Market Absolute $ Opportunity, 2019-2029
  • Figure 17: Global Oncolytic Virus Immunotherapy Market Analysis By End User -2019 & 2029
  • Figure 18: Global Oncolytic Virus Immunotherapy Market Y-o-Y Growth Projections by End User, 2019-2029
  • Figure 19: Global Oncolytic Virus Immunotherapy Market Attractiveness Analysis, By End User
  • Figure 20: Global Oncolytic Virus Immunotherapy Market Share Analysis (%) By Region, 2019 & 2029
  • Figure 21: Global Oncolytic Virus Immunotherapy Market Y-o-Y Growth (%) By Region, 2019-2029
  • Figure 22: Global Oncolytic Virus Immunotherapy Market Attractiveness Analysis, By Region
目次

Oncolytic Virus Immunotherapy Market - Scope of the Report

The latest publication by Persistence Market Research (PMR) on the global oncolytic virus immunotherapy market evaluates opportunities and current market landscape, and provides detailed analysis and updates about corresponding sections affecting the global oncolytic virus immunotherapy market. The study offers detailed insights on the key market dynamics, which includes drivers, restraints, trends, opportunities and comprehensive information on the market structure of oncolytic virus immunotherapy. The principal aim of the market study is to present exclusive information about how the market will perform in the forecast period of 2019-2029.

Important indicators for the successful growth of the oncolytic virus immunotherapy market are presented in this comprehensive report, which include supply chain analysis, value chain analysis, Year-on-Year (Y-o-Y) growth analysis of the market, and compounded annual growth rate (CAGR) which is described in an exhaustive way in PMR's research. This research study can support readers to know the demand for oncolytic virus immunotherapy's quantitative development opportunities over the study period.

The research is beneficial for shareholders in oncolytic virus immunotherapy, including oncolytic virus immunotherapy investors, manufacturers, distributors, and suppliers, and can help them in developing suitable business strategies to flourish in the oncolytic virus immunotherapy market. The insights and wisdom presented in this PMR's study can be leveraged by shareholders in the oncolytic virus immunotherapy market, industry experts, investors, researchers, reporters, as well as oncolytic virus immunotherapy business enthusiasts.

Market statistics as well as information linked to macro as well as microeconomic variables affecting the business scenario in the oncolytic virus immunotherapy market are also included in the current study. Depending on potential developments in the oncolytic virus immunotherapy market, substantive insights are also encountered in this report. Additionally, by virtue of the data submitted in this oncolytic virus immunotherapy report, minor companies and new entrants in the oncolytic virus immunotherapy industry can aid in making suitable company choices to achieve traction in the oncolytic virus immunotherapy market.

Key Questions Answered in PMR's Oncolytic Virus Immunotherapy Market Report

  • Which variables could alter the demand and supply for oncolytic virus immunotherapy during the evaluated and forecast period?
  • What are the restraints that investors need to be aware of that they might need to tackle while investing in the oncolytic virus immunotherapy market?
  • How clinical trials are providing growth opportunities for oncolytic virus immunotherapy market?
  • What are the developmental trends in oncolytic virus immunotherapy sector that will impact the market?
  • Which category of virus is in the prime focus of the manufactures?
  • Which regions will stay the most lucrative markets for market participants in oncolytic virus immunotherapy?
  • How businesses in the oncolytic virus immunotherapy market can avail the growth opportunities in developed and emerging sectors?

Oncolytic Virus Immunotherapy Market: Research Methodology

PMR is committed to provide unbiased market research solutions to its clients. A distinctive research methodology has been used to perform comprehensive research on the development of the oncolytic virus immunotherapy market, and to achieve findings on the market's potential development parameters. This study design is a composition of primary and secondary research that enables analysts to ensure findings are accurate and reliable.

During the development of the oncolytic virus immunotherapy market report the secondary studies referred by analysts comprises of companies annual reports, trade journals, white papers, statistics from governmental institutions, and internal and external proprietary databases as well. Analysts have also considered opinions from product portfolio managers, and industry experts, who contributed primary insights for the development of this report.

Comprehensive data obtained from primary and secondary resources functions as an affirmation by companies in the oncolytic virus immunotherapy market, making PMR's assessment of the market's development opportunities for the oncolytic virus immunotherapy market more precise and credible.

Table of Contents

1. Executive Summary

  • 1.1. Global Market Outlook
  • 1.2. Demand Side Trends
  • 1.3. Supply Side Trends
  • 1.4. Analysis and Recommendations

2. Market Overview

  • 2.1. Market Coverage / Taxonomy
  • 2.2. Market Definition / Scope / Limitations

3. Key Market Trends

  • 3.1. Key Trends Impacting the Market
  • 3.2. Product Innovation / Development Trends

4. Key Inclusions

  • 4.1. Product Adoption / Usage Analysis
  • 4.2. Product USPs / Features
  • 4.3. Establishing Industry - Institutional Partnerships
  • 4.4. Identifying Unique Delivery Methods for Oncolytic Virus Therapy

5. Global Oncolytic Virus Immunotherapy Market Demand (in Value or Size in US$ Mn) Analysis 2015-2018 and Forecast, 2019-2029

  • 5.1. Historical Market Value (US$ Mn) Analysis, 2015-2018
  • 5.2. Current and Future Market Value (US$ Mn) Projections, 2019-2029
    • 5.2.1. Y-o-Y Growth Trend Analysis
    • 5.2.2. Absolute $ Opportunity Analysis

6. Market Background

  • 6.1. Macro-Economic Factors
    • 6.1.1. Global GDP Growth Outlook
    • 6.1.2. Global Healthcare Industry Outlook
  • 6.2. Forecast Factors - Relevance & Impact
    • 6.2.1. Adoption of Oncolytic Virus Immunotherapy
    • 6.2.2. Ongoing Clinical Trials
    • 6.2.3. Regulatory Imposition on Oncolytic Virus Immunotherapy
    • 6.2.4. Advancements in Oncolytic Virus Immunotherapy
    • 6.2.5. Incremental R&D by Product-Based Companies
  • 6.3. Regulatory Scenario for GMP
  • 6.4. Value Chain
  • 6.5. Market Dynamics
    • 6.5.1. Drivers
    • 6.5.2. Restraints
    • 6.5.3. Opportunity Analysis

7. Global Oncolytic Virus Immunotherapy Market - Venture Capital Financing

8. Global Oncolytic Virus Immunotherapy Market -Pipeline Analysis

9. Global Oncolytic Virus Immunotherapy Market Analysis 2015-2018 and Forecast 2019-2029, by Indication

  • 9.1. Introduction / Key Findings
  • 9.2. Historical Market Size (US$ Mn) Analysis By Indication, 2014 - 2018
  • 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Indication, 2019 - 2029
    • 9.3.1. Melanoma
  • 9.4. Market Attractiveness Analysis By Indication

10. Global Oncolytic Virus Immunotherapy Market Analysis 2015-2018 and Forecast 2019-2029, By End User

  • 10.1. Introduction / Key Findings
  • 10.2. Historical Market Size (US$ Mn) Analysis By End User, 2014 - 2018
  • 10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By End User, 2019 - 2029
    • 10.3.1. Hospitals
    • 10.3.2. Specialty Clinics
    • 10.3.3. Cancer Research Institutes
  • 10.4. Market Attractiveness Analysis By End User

11. Global Oncolytic Virus Immunotherapy Market Analysis 2015-2018 and Forecast 2019-2029, by Region

  • 11.1. Introduction
  • 11.2. Historical Market Size (US$ Mn) Analysis By Region, 2014 - 2018
  • 11.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2019 - 2029
    • 11.3.1. North America
    • 11.3.2. Europe
  • 11.4. Market Attractiveness Analysis By Region

12. Competition Analysis

  • 12.1. Competition Dashboard
  • 12.2. Competition Deep Dive
    • 12.2.1. BioVex, Inc. (Amgen, Inc.)
      • 12.2.1.1. Overview
      • 12.2.1.2. Product Portfolio
      • 12.2.1.3. Profitability by Market Segments (Product/Channel/Region)
      • 12.2.1.4. Sales Footprint
      • 12.2.1.5. Strategy Overview
        • 12.2.1.5.1. Marketing Strategy
        • 12.2.1.5.2. Product Strategy
        • 12.2.1.5.3. Channel Strategy
    • 12.2.2. Cold Genesys, Inc.
      • 12.2.2.1. Overview
      • 12.2.2.2. Product Portfolio
      • 12.2.2.3. Profitability by Market Segments (Product/Channel/Region)
      • 12.2.2.4. Sales Footprint
      • 12.2.2.5. Strategy Overview
        • 12.2.2.5.1. Marketing Strategy
        • 12.2.2.5.2. Product Strategy
        • 12.2.2.5.3. Channel Strategy
    • 12.2.3. DNAtrix Therapeutics
      • 12.2.3.1. Overview
      • 12.2.3.2. Product Portfolio
      • 12.2.3.3. Profitability by Market Segments (Product/Channel/Region)
      • 12.2.3.4. Sales Footprint
      • 12.2.3.5. Strategy Overview
        • 12.2.3.5.1. Marketing Strategy
        • 12.2.3.5.2. Product Strategy
        • 12.2.3.5.3. Channel Strategy
    • 12.2.4. Genelux Corporation
      • 12.2.4.1. Overview
      • 12.2.4.2. Product Portfolio
      • 12.2.4.3. Profitability by Market Segments (Product/Channel/Region)
      • 12.2.4.4. Sales Footprint
      • 12.2.4.5. Strategy Overview
        • 12.2.4.5.1. Marketing Strategy
        • 12.2.4.5.2. Product Strategy
        • 12.2.4.5.3. Channel Strategy
    • 12.2.5. Lokon Pharma AB
      • 12.2.5.1. Overview
      • 12.2.5.2. Product Portfolio
      • 12.2.5.3. Profitability by Market Segments (Product/Channel/Region)
      • 12.2.5.4. Sales Footprint
      • 12.2.5.5. Strategy Overview
        • 12.2.5.5.1. Marketing Strategy
        • 12.2.5.5.2. Product Strategy
        • 12.2.5.5.3. Channel Strategy
    • 12.2.6. Oncolytics Biotech, Inc.
      • 12.2.6.1. Overview
      • 12.2.6.2. Product Portfolio
      • 12.2.6.3. Profitability by Market Segments (Product/Channel/Region)
      • 12.2.6.4. Sales Footprint
      • 12.2.6.5. Strategy Overview
        • 12.2.6.5.1. Marketing Strategy
        • 12.2.6.5.2. Product Strategy
        • 12.2.6.5.3. Channel Strategy
    • 12.2.7. ORYX GmbH & Co. KG
      • 12.2.7.1. Overview
      • 12.2.7.2. Product Portfolio
      • 12.2.7.3. Profitability by Market Segments (Product/Channel/Region)
      • 12.2.7.4. Sales Footprint
      • 12.2.7.5. Strategy Overview
        • 12.2.7.5.1. Marketing Strategy
        • 12.2.7.5.2. Product Strategy
        • 12.2.7.5.3. Channel Strategy
    • 12.2.8. PsiOxus Therapeutics
      • 12.2.8.1. Overview
      • 12.2.8.2. Product Portfolio
      • 12.2.8.3. Profitability by Market Segments (Product/Channel/Region)
      • 12.2.8.4. Sales Footprint
      • 12.2.8.5. Strategy Overview
        • 12.2.8.5.1. Marketing Strategy
        • 12.2.8.5.2. Product Strategy
        • 12.2.8.5.3. Channel Strategy
    • 12.2.9. SillaJen, Inc.
      • 12.2.9.1. Overview
      • 12.2.9.2. Product Portfolio
      • 12.2.9.3. Profitability by Market Segments (Product/Channel/Region)
      • 12.2.9.4. Sales Footprint
      • 12.2.9.5. Strategy Overview
        • 12.2.9.5.1. Marketing Strategy
        • 12.2.9.5.2. Product Strategy
        • 12.2.9.5.3. Channel Strategy
    • 12.2.10. Sorrento Therapeutics, Inc.
      • 12.2.10.1. Overview
      • 12.2.10.2. Product Portfolio
      • 12.2.10.3. Profitability by Market Segments (Product/Channel/Region)
      • 12.2.10.4. Sales Footprint
      • 12.2.10.5. Strategy Overview
        • 12.2.10.5.1. Marketing Strategy
        • 12.2.10.5.2. Product Strategy
        • 12.2.10.5.3. Channel Strategy
    • 12.2.11. Takara Bio
      • 12.2.11.1. Overview
      • 12.2.11.2. Product Portfolio
      • 12.2.11.3. Profitability by Market Segments (Product/Channel/Region)
      • 12.2.11.4. Sales Footprint
      • 12.2.11.5. Strategy Overview
        • 12.2.11.5.1. Marketing Strategy
        • 12.2.11.5.2. Product Strategy
        • 12.2.11.5.3. Channel Strategy
    • 12.2.12. Targovax ASA
      • 12.2.12.1. Overview
      • 12.2.12.2. Product Portfolio
      • 12.2.12.3. Profitability by Market Segments (Product/Channel/Region)
      • 12.2.12.4. Sales Footprint
      • 12.2.12.5. Strategy Overview
        • 12.2.12.5.1. Marketing Strategy
        • 12.2.12.5.2. Product Strategy
        • 12.2.12.5.3. Channel Strategy
    • 12.2.13. Transgene sa
      • 12.2.13.1. Overview
      • 12.2.13.2. Product Portfolio
      • 12.2.13.3. Profitability by Market Segments (Product/Channel/Region)
      • 12.2.13.4. Sales Footprint
      • 12.2.13.5. Strategy Overview
        • 12.2.13.5.1. Marketing Strategy
        • 12.2.13.5.2. Product Strategy
        • 12.2.13.5.3. Channel Strategy
    • 12.2.14. Turnstone Biologics
      • 12.2.14.1. Overview
      • 12.2.14.2. Product Portfolio
      • 12.2.14.3. Profitability by Market Segments (Product/Channel/Region)
      • 12.2.14.4. Sales Footprint
      • 12.2.14.5. Strategy Overview
        • 12.2.14.5.1. Marketing Strategy
        • 12.2.14.5.2. Product Strategy
        • 12.2.14.5.3. Channel Strategy
    • 12.2.15. VCN Biosciences
      • 12.2.15.1. Overview
      • 12.2.15.2. Product Portfolio
      • 12.2.15.3. Profitability by Market Segments (Product/Channel/Region)
      • 12.2.15.4. Sales Footprint
      • 12.2.15.5. Strategy Overview
        • 12.2.15.5.1. Marketing Strategy
        • 12.2.15.5.2. Product Strategy
        • 12.2.15.5.3. Channel Strategy
    • 12.2.16. Viralytics Ltd. (Merck & Co., Inc.)
      • 12.2.16.1. Overview
      • 12.2.16.2. Product Portfolio
      • 12.2.16.3. Profitability by Market Segments (Product/Channel/Region)
      • 12.2.16.4. Sales Footprint
      • 12.2.16.5. Strategy Overview
        • 12.2.16.5.1. Marketing Strategy
        • 12.2.16.5.2. Product Strategy
        • 12.2.16.5.3. Channel Strategy
    • 12.2.17. Vyriad
      • 12.2.17.1. Overview
      • 12.2.17.2. Product Portfolio
      • 12.2.17.3. Profitability by Market Segments (Product/Channel/Region)
      • 12.2.17.4. Sales Footprint
      • 12.2.17.5. Strategy Overview
        • 12.2.17.5.1. Marketing Strategy
        • 12.2.17.5.2. Product Strategy
        • 12.2.17.5.3. Channel Strategy
    • 12.2.18. Shanghai Sunway Biotech
      • 12.2.18.1. Overview
      • 12.2.18.2. Product Portfolio
      • 12.2.18.3. Profitability by Market Segments (Product/Channel/Region)
      • 12.2.18.4. Sales Footprint
      • 12.2.18.5. Strategy Overview
        • 12.2.18.5.1. Marketing Strategy
        • 12.2.18.5.2. Product Strategy
        • 12.2.18.5.3. Channel Strategy

13. Assumptions and Acronyms Used

14. Research Methodology